Teacher Retirement System of Texas Boosts Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Teacher Retirement System of Texas increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 74,425 shares of the medical equipment provider’s stock after purchasing an additional 10,267 shares during the period. Teacher Retirement System of Texas’ holdings in Zimmer Biomet were worth $7,862,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in ZBH. Stonebridge Financial Group LLC purchased a new position in Zimmer Biomet in the fourth quarter valued at about $25,000. Dunhill Financial LLC increased its holdings in Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares in the last quarter. Brooklyn Investment Group purchased a new position in Zimmer Biomet in the third quarter valued at about $35,000. Kentucky Trust Co purchased a new position in Zimmer Biomet in the fourth quarter valued at about $39,000. Finally, OFI Invest Asset Management purchased a new position in Zimmer Biomet in the fourth quarter valued at about $40,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.95% of the stock is owned by company insiders.

Zimmer Biomet Stock Down 0.9 %

Shares of NYSE ZBH opened at $110.79 on Friday. The firm has a market cap of $22.05 billion, a P/E ratio of 24.90, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The firm’s 50 day moving average price is $106.74 and its 200 day moving average price is $106.86. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $133.90. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the firm posted $2.20 EPS. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Analysts Set New Price Targets

ZBH has been the subject of a number of research analyst reports. Barclays dropped their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. Raymond James dropped their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. JMP Securities reissued a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 7th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and an average price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.